MedeliX
Start asking

Perindopril

Aceper, Coversyl, Padero, Periday · ATC code C09AA04

Also known as: Perindopril Erbumine · Brand names: Aceper, Coversyl, Padero, Periday, Perpril, Raten, Serperil

Key facts
Active substance
Perindopril
Drug class
ACE inhibitor
ATC code
C09AA04
Authorisation
authorised nationally; no central EU authorisation
Information as of
2026-10-29

Boxed warning

  • When pregnancy is detected, discontinue perindopril erbumine as soon as possible [see Warnings and Precautions (5.4) ].
  • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.4) ].

Key facts

Perindopril (as perindopril erbumine) is an ACE inhibitor. Per the US prescribing information, it is used for essential hypertension and stable coronary artery disease.

What it is used for

  • Essential hypertension, alone or with other antihypertensives, especially thiazide diuretics
  • Stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction

Dosing

  • Hypertension: start with 4 mg once a day, titrate as needed to a maximum of 16 mg per day; usual maintenance 4 mg to 8 mg in one or two doses
  • Elderly hypertensive patients: initially 4 mg daily; doses above 8 mg only with careful blood pressure monitoring
  • Stable CAD: 4 mg once daily for 2 weeks, then 8 mg once daily; over 70 years: 2 mg in the first week, 4 mg in the second week, then 8 mg once daily
  • On diuretics: consider reducing the diuretic dose before starting
  • Renal impairment: not recommended with creatinine clearance below 30 mL/min; with lesser impairment start with 2 mg/day, maximum 8 mg/day

Contraindications

  • Hypersensitivity (including angioedema) to perindopril or any other ACE inhibitor
  • Hereditary or idiopathic angioedema
  • Co-administration with aliskiren in patients with diabetes
  • Combination with a neprilysin inhibitor (e.g. sacubitril); do not give within 36 hours of switching to or from sacubitril/valsartan

Important warnings

  • Boxed warning: fetal toxicity – discontinue as soon as possible when pregnancy is detected
  • Head and neck angioedema (0.1% in US trials), possibly fatal with tongue or larynx involvement; increased risk with mTOR or neprilysin inhibitors
  • Symptomatic hypotension, especially in patients on diuretics
  • Neutropenia/agranulocytosis, impaired renal function, hyperkalemia
  • Cough

Side effects

  • Cough (12% vs 4.5% on placebo) and back pain (5.8% vs 3.1%)
  • Dizziness (dose-related), headache, asthenia
  • Hypotension, angioedema, hyperkalemia

Interactions

  • Diuretics: excessive blood pressure fall at the start of therapy
  • Potassium supplements and potassium-sparing diuretics: hyperkalemia
  • Lithium: increased lithium levels and toxicity; monitor levels frequently
  • NSAIDs including COX-2 inhibitors: worsening renal function in elderly or volume-depleted patients
  • Injectable gold: rare nitritoid reactions

Pregnancy and breastfeeding

  • Discontinue as soon as possible when pregnancy is detected; can injure and kill the developing fetus

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Patient information (US)

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

Turkey

  • AceperGENVEON İLAÇ SAN. VE TİC. A.Ş. · 3 register entries
  • CoversylSERVIER İLAÇ VE ARAŞTIRMA A.Ş. · 3 register entries
  • PaderoNOBEL İLAÇ SAN. VE TİC. A.Ş. · 3 register entries
  • PeridayNEUTEC İLAÇ SAN. TİC. A.Ş · 6 register entries
  • PerprilHELBA İLAÇ İÇ VE DIŞ SAN. TİC. A.Ş. · 1 register entry
  • RatenASET İLAÇ SAN. VE TİC. A.Ş. · 2 register entries
  • SerperilSANOVEL İLAÇ SAN. VE TİC. A.Ş. · 3 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 8 more European countries
Belgium
Perindopril Eg
Czechia
Perindopril Arginine Stada
France
Perindopril Arginine Eg
Ireland
Perindopril Arginine Clonmel
Italy
Perindopril Eg
Luxembourg
Perindopril Eg
Malta
Perindopril Arginine Clonmel
Slovakia
Perindopril Stada

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Related calculators

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. U.S. Food and Drug Administration. Perindopril Erbumine (Aurobindo Pharma Limited) – Prescribing Information, 2024-03-13. DailyMed (NLM), 2026-10-29. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87768fbf-7c63-47da-8925-0316f343d6ef
  2. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  3. Wikidata (CC0): ATC C09AA.

Editorial: Medelix editorial team · last updated 2026-10-29 · How these pages are made · Report an error

Source: U.S. Food and Drug Administration (FDA), prescribing information, via DailyMed (NLM); public domain. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.